Results 91 to 100 of about 48,845 (222)

Efficacy of bevacizumab-doxycycline and sunitinib-hesperitin combinations on experimentally-induced corneal neovascularization [PDF]

open access: yes, 2016
Tıp Fakültesi, Göz Hastalıkları Ana Bilim DalıAmaç: Topikal aflibersept, sunitinib, bevacizumab-doksisiklin, sunitinib-doksisiklin ve sunitinib-hesperitin kombinasyonlarının korneal neovaskülarizasyon (KNV), apopitozis ve fibrozisi önleyici etkilerinin ...
Ekim, Yeliz
core   +1 more source

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

open access: yesJournal of Experimental & Clinical Cancer Research, 2020
Background Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment ...
Ninadh M. D’Costa   +11 more
doaj   +1 more source

Sunitinib Causes Macrocytosis in Patients with Advanced Renal Cell Carcinoma

open access: yes, 2010
Background: Sunitinib is approved for treatment of advanced renal cell carcinoma (RCC). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation.
J. Price, R. Shaarbaf, L. Wood
core   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

open access: yesJournal of Applied Toxicology, Volume 46, Issue 12, Page 4583-4598, December 2026.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü   +3 more
wiley   +1 more source

Ultra‐High Frequency Ultrasound Imaging and Quantification of Microvascular Flow in Xenograft Renal Cell Carcinoma in an Avian Chorioallantoic Membrane Model

open access: yesJournal of Ultrasound in Medicine, Volume 45, Issue 12, Page 2691-2709, December 2026.
Patient‐derived xenograft (PDX) tumor models initiated in avian chorioallantoic membranes (CAM) are under investigation to evaluate the effectiveness of therapeutic options with the objective of personalizing treatments. CAM PDXs paired with ultra‐high frequency ultrasound (UHFUS) imaging could potentially constitute prospective high throughput assays ...
Sara Mar   +5 more
wiley   +1 more source

3158 Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model

open access: yesJournal of Clinical and Translational Science, 2019
OBJECTIVES/SPECIFIC AIMS: The aims of this study are threefold. Firstly, we are examining the effects of increased in vitro afterload (a proxy for hypertension) on human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) response to sunitinib in a ...
Carissa Livingston   +5 more
doaj   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Experience with sunitinib in the treatment of metastatic renal cell carcinoma

open access: yesTherapeutic Advances in Urology, 2012
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the treatment of patients with metastatic renal cell carcinoma (mRCC) in Europe and the USA in 2006, the agent has had a substantial impact on the treatment ...
Manuela Schmidinger   +2 more
doaj   +1 more source

Chemical structures of sorafenib and sunitinib.

open access: yes, 2014
Chemical structures of sorafenib and sunitinib.
Kazuhiko Yamashita (596927)   +12 more
core   +1 more source

Guillain-Barré Syndrome following Treatment with Sunitinib Malate [PDF]

open access: yes, 2014
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects ...
Sandip Saha   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy